Wybrane adipocytokiny i ich potencjalne zastosowanie w kontroli przebiegu przewlekłego wirusowego zapalenia wątroby typu B i C
 
Więcej
Ukryj
1
Oddział Chorób Wewnętrznych II, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku
2
Oddział Endokrynologii i Diabetologii, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku
3
Zakład Patofizjologii Katedry Patofizjologii i Endokrynologii Wydziału Lekarskiego z Oddziałem Lekarsko-Dentystycznym w Zabrzu Śląskiego Uniwersytetu Medycznego w Katowicach
AUTOR DO KORESPONDENCJI
Joanna Olszok   

Oddział Chorób Wewnętrznych II, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku, ul. Energetyków 46, 42-200 Rybnik, tel. 32 429 12 51
 
Ann. Acad. Med. Siles. 2015;69:1–7
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Przewlekłe wirusowe zapalenie wątroby (WZW) typu B i C należą do najczęstszych chorób wątroby. Długotrwały proces martwiczo-zapalny może prowadzić do groźnych dla życia powikłań, choć u niektórych pacjentów stan wątroby jest stabilny przez wiele lat. Ze względu na zróżnicowane rokowanie w przebiegu przewlekłego wirusowego zapalenia wątroby (PWZW) typu B i C, poszukuje się obecnie dodatkowych czynników hamujących postęp tych chorób. Obiektem wielu badań stały się adipocytokiny, substancje o wielokierunkowym oddziaływaniu, wytwarzane m.in. przez komórki tkanki tłuszczowej. W pracy przedstawiono wzajemne zależności wybranych adipocytokin i WZW typu B i C oraz potencjalne wykorzystanie tej wiedzy w praktyce lekarskiej.
 
REFERENCJE (74)
1.
Tuchacz S., Gruchała M., Karbowska J., Kochan Z., Sobiczewski W., Rynkiewicz A. Adiponektyna w chorobie wieńcowej – przegląd piśmiennictwa. Pol. Prz. Kardiol. 2007; 9: 215–219.
 
2.
Niemczyk S., Romejko-Ciepielewska K., Niemczyk L. Zaburzenia funkcji hormonalnej tkanki tłuszczowej i w zakresie hormonów płciowych u chorych z przewlekłą niewydolnością nerek. Endokrynol. Pol. 2012; 63: 148–155.
 
3.
Olszanecka-Glinianowicz M., Handzlik-Orlik G., Orlik B., Chudek J. Rola adipokin w patogenezie nieswoistych zapaleń jelita grubego. Endokrynol. Pol. 2013; 64: 226–231.
 
4.
Rystwej-Niedźwiedzka P., Deptuła W. Tkanka tłuszczowa a układ odpornościowy. Alergia Astma Immunol. 2009; 15: 101–105.
 
5.
Pluskiewicz W., Adamczyk P., Marek B. i wsp. Adiponektyna i rezystyna a stan szkieletu u kobiet uczestniczących w badaniu RAC-OST-POL. Endokrynol. Pol. 2012; 63: 427–431.
 
6.
Gałecka-Wanatowicz D., Chomyszyn-Gajewska M. Otyłość a stan tkanek przyzębia – przegląd piśmiennictwa. Czas. Stomat. 2009; 62: 649–656.
 
7.
Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957–969.
 
8.
Pajvani U.B., Du X., Combs T.P. i wsp. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. 2003; 278: 9073–9085.
 
9.
Weyer C., Funahashi T., Tanaka S. i wsp. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86: 1930–1935.
 
10.
Miyazaki T., Shimada K., Mokuno H., Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart 2003; 89: 663.
 
11.
Shimada K., Miyazaki T., Daida H. Adiponectin and atherosclerotic disease. Clin. Chim. Acta 2004; 344: 1–12.
 
12.
Tacke F., Wüstefeld T., Horn R. i wsp. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005; 42: 666–673.
 
13.
Tsochatzis E., Papatheodoridis G.V., Hadziyannis E. i wp. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand. J. Gastroenterol. 2008; 43: 1128–1136.
 
14.
Siagris D., Vafiadis G., Michalaki M. i wsp. Serum adiponectin in chronic hepatitis C and B. J. Viral. Hepat. 2007; 14: 577–583.
 
15.
Liu C.J., Chen P.J., Lai M.Y. i wsp. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol. Int. 2009; 3: 364–370.
 
16.
Hui C.K., Zhang H.Y., Lee N.P. i wsp. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J. Hepatol. 2007; 47: 191–202.
 
17.
Wong V.W., Wong G.L., Yu J. i wsp. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am. J. Gastroenterol. 2010; 105: 132–138.
 
18.
Lu J.Y., Su T.C., Liu Y.H., Hsu H.J., Chen C.L., Yang W.S. Lower plasma adiponectin is correlated to higher alanine aminotransferase independent of metabolic factors and hepatitis B virus carrier status. Intern. Med. J. 2007; 37: 365–371.
 
19.
Korah T.E., El-Sayed S., Elshafie M.K., Hammoda G.E., Safan M.A. Signifi-cance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J. Hepatol. 2013; 5: 74–81.
 
20.
Jonsson J.R., Moschen A.R., Hickman I.J. i wsp. Adiponectin and its recep-tors in patients with chronic hepatitis C. J. Hepatol. 2005, 436: 929–936.
 
21.
Costantini S., Capone F., Guerriero E. i wsp. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 2012; 7: e39486.
 
22.
Petit J.M., Minello A., Jooste V. i wsp. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J. Clin. Endocrinol. Metab. 2005; 90: 2240–2243.
 
23.
Liu C.J., Chen P.J., Jeng Y.M. i wsp. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J. Hepatol. 2005; 43: 235–242.
 
24.
Ashour E., Samy N., Sayed M., Imam A. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. Clin. Lab. 2010; 56: 103–110.
 
25.
Wang A.Y., Hickman I.J., Richards A.A., Whitehead J.P., Prins J.B., Macdonald G.A. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am. J. Gastroenterol. 2005; 100: 2717–2723.
 
26.
Zografos T.A., Liaskos C., Rigopoulou E.I. i wsp. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am. J. Gastroenterol. 2008; 103: 605–614.
 
27.
Kara B., Gunesacar R., Doran F., Kara I.O., Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv. Ther. 2007; 24: 972–982.
 
28.
Meng Q.H., Duan Z.H., Lin Z.H., Yu H.W., Li J., Liu Y. Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C. Dig. Dis. Sci. 2009; 54: 1120–1127.
 
29.
Latif H.A., Assal H.S., Mahmoud M., Rasheed W.I. Role of serum adiponec-tin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin. Exp. Med. 2011; 11: 123–129.
 
30.
Fukushima N., Kuromatsu R., Arinaga-Hino T. i wsp. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol. Res. 2010; 40: 911–922.
 
31.
Palmer C., Hampartzoumian T., Lloyd A., Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008; 48: 374–384.
 
32.
Lu J.Y., Chuang L.M., Yang W.S. i wsp. Adiponectin levels among patients with chronic hepatitis B and C infections and in response.
 
33.
to IFN-alpha therapy. Liver Int. 2005; 25: 752–759.
 
34.
Khattab M.A., Eslam M., Shatat M. i wsp. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J. Gastrointestin. Liver Dis. 2012; 21: 59–65.
 
35.
Saad Y., Ahmed A., Saleh D.A., Doss W. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur. J. Gastroenterol. Hepatol. 2013; 25: 920–925.
 
36.
Matkovic V., Ilich J.Z., Badenhop N.E. i wsp. Gain in body fat is inversely related to the nocturnal rise in serum leptin level in young females. J. Clin. Endocrinol. Metab. 1997; 82: 1368–1372.
 
37.
Tungtrongchitr R., Treeprasertsuk S., Ei N.N., Thepouyporn A., Phonrat B., Huntrup A. Serum leptin concentrations in chronic hepatitis. J. Med. Assoc. Thai. 2006; 89: 490–499.
 
38.
Testa R., Franceschini R., Giannini E. i wsp. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J. Hepatol. 2000; 33: 33–37.
 
39.
Żwirska-Korczala K., Kukla M., Ziółkowski A. i wsp. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp. Clin. Hep. 2005; 1: OR60-5.
 
40.
Giannini E., Ceppa P., Botta F. i wsp. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am. J. Gastroenterol. 2000; 95: 3211–3217.
 
41.
Baranova A., Jarrar M.H., Stepanova M. i wsp. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion 2011; 83: 32–40.
 
42.
Piche T., Vandenbos F., Abakar-Mahamat A. i wsp. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J. Viral. Hepat. 2004; 11: 91–96.
 
43.
Kukla M., Żwirska-Korczala K., Gabriel A. i wsp. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J. Viral. Hepat. 2010; 17: 661–667.
 
44.
Bolukbas F.F., Bolukbas C., Horoz M. i wsp. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterol. 2004; 4: 23.
 
45.
El-Gindy E.M., Ali-Eldin F.A., Meguid M.A. Serum leptin level and its association with fatigue in patients with chronic hepatitis C virus infection. Arab. J. Gastroenterol. 2012; 13: 54–57.
 
46.
Gordon A., McLean C.A., Pedersen J.S., Bailey M.J., Roberts S.K. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J. Hepatol. 2005; 43: 38–44.
 
47.
Myers R.P., Messous D., Poynard T., Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can. J. Gastroenterol. 2007; 21: 289–294.
 
48.
Zografos T.A., Rigopoulou E.I., Liaskos C. i wsp. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J. Hepatol. 2006; 44: 848–855.
 
49.
Eguchi Y., Mizuta T., Yasutake T. i wsp. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J. Gastroenterol. 2006; 12: 556–560.
 
50.
Manolakopoulos S., Bethanis S., Liapi C. i wsp. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol. 2007; 7: 17.
 
51.
Steppan C.M., Brown E.J., Wright C.M. i wsp. A family of tissue−specific resistin−like molecules. Proc. Natl. Acad. Sci. U S A 2001; 98: 502–506.
 
52.
Pang S.S., Le Y.Y. Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 2006; 3: 29–34.
 
53.
Wang H., Chu W., Hemphill C., Elbein S. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J. Clin. Endocr. Metab. 2002; 87: 2520–2524.
 
54.
Karbowska A., Boratyńska M., Klinger M. Rezystyna – czynnik patogenetyczny czy biomarker zaburzeń metabolicznych i zapalenia? Postepy Hig. Med. Dosw. 2009; 63: 485–491.
 
55.
Morace C., Spadaro A., Cucunato M. i wsp. High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder. Hepatogastroenterology 2010; 57: 1215–1219.
 
56.
Durazzo M., Belci P., Niro G. i wsp. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J. Endocrinol. Invest. 2013; 36: 600–605.
 
57.
Zhang L.Q., Heruth D.P., Ye S.Q. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 2011; 3: 13–25.
 
58.
Cybulska B. Komentarz redakcyjny: Wisfatyna – co dotychczas wiadomo o jej roli w fizjologii i patologii? Kardiol. Pol. 2011; 69: 808–809.
 
59.
Benedict C., Shostak A., Lange T. i wsp. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. J. Clin. Endocrinol. Metab. 2012; 97: E218–222.
 
60.
Fukuhara A., Matsuda M., Nishizawa M. i wsp. Visfatin: a protein secrated by visceral fat that mimics the effects of insulin. Science 2005; 21: 426–430.
 
61.
Berndt J., Kloting N., Kralisch S. i wsp. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54; 2911–2916.
 
62.
Rubbia-Brandt L., Fabris P., Paganin S. i wsp. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406–412.
 
63.
Kukla M., Żwirska-Korczala K., Gabriel A. i wsp. Visfatin serum levels in chronic hepatitis C patients. J. Viral. Hepat. 2010; 17: 254–260.
 
64.
Moschen A.R., Kaser A., Enrich B. i wsp. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007; 178: 1748–1758.
 
65.
Hano A.E., Deghady A., Shaaban S., Rahman M. Serum Visfatin in patients with chronic hepatitis C. Am. J. Sci. 2011; 7: 94–101.
 
66.
Chen L., Liu W., Lai S., Li Y., Wang X., Zhang H. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur. J. Gastroenterol. Hepatol. 2013; 25: 935–941.
 
67.
Huang J.F., Huang C.F., Yu M.L. i wsp. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 2011; 26: 530–535.
 
68.
Kukla M., Mazur W., Bułdak R.J., Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol. Med. 2011; 17: 1397–1410.
 
69.
Kukla M., Waluga M., Sawczyn T. i wsp. Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. Pol. J. Pathol. 2012; 63: 213–220.
 
70.
Principe A., Melgar-Lesmes P., Fernández-Varo G. i wsp. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008; 48: 1193–1201.
 
71.
El-Mesallamy H.O., Hamdy N.M., Rizk H.H., El-Zayadi A.R. Apelin serum level in Egyptian patients with chronic hepatitis C. Mediators Inflamm. 2011; 2011: 703031.
 
72.
Tonelli J., Li W., Kishore P. i wsp. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621-9. Erratum in: Diabetes 2005; 54: 587.
 
73.
Furuhashi M., Ura N., Takizawa H. i wsp. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 2004; 22: 1977–1982.
 
74.
Shimada K., Kawarabayashi T., Tanaka A. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res. Clin. Pract. 2004; 65: 227–234.
 
eISSN:1734-025X